Armune BioScience Inc. granted AEterna Zentaris Inc. rights to sell its Apifiny prostate cancer diagnostic to designated medical professionals in the US. For those tests that it markets, AEterna gets sales commissions. (Dec.)
Apifiny is the only cancer-specific non-PSA blood test for prostate cancer. It tests for autoantibodies produced by the immune system in response to cancer, providing physicians with an avenue for earlier detection and treatment planning